Literature DB >> 17257813

The skeletal muscle-specific glycogen-targeted protein phosphatase 1 plays a major role in the regulation of glycogen metabolism by adrenaline in vivo.

Barry J Toole1, Patricia T W Cohen.   

Abstract

Adrenaline and insulin are the major hormones regulating glycogen metabolism in skeletal muscle. We have investigated the effects of these hormones on the rate-limiting enzymes of glycogen degradation and synthesis (phosphorylase and glycogen synthase respectively) in GM-/- mice homozygous for a null allele of the major skeletal muscle glycogen targeting subunit (GM) of protein phosphatase 1 (PP1). Hyperphosphorylation of Ser14 in phosphorylase, and Ser7, Ser640 and Ser640/644 of GS, in the skeletal muscle of GM-/- mice compared with GM+/+ mice indicates that the PP1-GM complex is the major phosphatase that dephosphorylates these sites in vivo. Adrenaline caused a 2.4-fold increase in the phosphorylase (-/+AMP) activity ratio in the skeletal muscle of control mice compared to a 1.4 fold increase in GM-/- mice. Adrenaline also elicited a 67% decrease in the GS (-/+G6P) activity ratio in control mice but only a small decrease in the skeletal muscle of GM-/- mice indicating that GM is required for the full response of phosphorylase and GS to adrenaline. PP1-GM activity and the amount of PP1 bound to GM decreased 40% and 45% respectively, in response to adrenaline in control mice. The data support a model in which adrenaline stimulates phosphorylation of phosphorylase Ser14 and GS Ser7 in GM+/+ mice by both kinase activation and PP1-GM inhibition and the phosphorylation of GS Ser640 and Ser640/644 by PP1-GM inhibition alone. Insulin decreased the phosphorylation of GS Ser640 and Ser640/644 and stimulated the GS (-/+G6P) activity ratio by approximately 2-fold in the skeletal muscle of either GM-/- and or control mice, but the low basal and insulin stimulated GS activity ratios in GM-/- mice indicate that PP1-GM is essential for maintaining normal basal and maximum insulin stimulated GS activity ratios in vivo.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17257813     DOI: 10.1016/j.cellsig.2006.11.013

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  6 in total

1.  Dok3-protein phosphatase 1 interaction attenuates Card9 signaling and neutrophil-dependent antifungal immunity.

Authors:  Jia Tong Loh; Shengli Xu; Jian Xin Huo; Susana Soo-Yeon Kim; Yue Wang; Kong-Peng Lam
Journal:  J Clin Invest       Date:  2019-06-10       Impact factor: 14.808

2.  AMP-activated protein kinase (AMPK)α2 plays a role in determining the cellular fate of glucose in insulin-resistant mouse skeletal muscle.

Authors:  R S Lee-Young; J S Bonner; W H Mayes; I Iwueke; B A Barrick; C M Hasenour; L Kang; D H Wasserman
Journal:  Diabetologia       Date:  2012-12-08       Impact factor: 10.122

Review 3.  The alpha,alpha-difluorinated phosphonate L-pSer-analogue: an accessible chemical tool for studying kinase-dependent signal transduction.

Authors:  Kaushik Panigrahi; MariJean Eggen; Jun-Ho Maeng; Quanrong Shen; David B Berkowitz
Journal:  Chem Biol       Date:  2009-09-25

4.  A limited role for PI(3,4,5)P3 regulation in controlling skeletal muscle mass in response to resistance exercise.

Authors:  D Lee Hamilton; Andrew Philp; Matthew G MacKenzie; Keith Baar
Journal:  PLoS One       Date:  2010-07-16       Impact factor: 3.240

Review 5.  Functions and therapeutic potential of protein phosphatase 1: Insights from mouse genetics.

Authors:  Mónica Ferreira; Monique Beullens; Mathieu Bollen; Aleyde Van Eynde
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2018-07-26       Impact factor: 4.739

6.  Variability in porcine microRNA genes and its association with mRNA expression and lipid phenotypes.

Authors:  Emilio Mármol-Sánchez; María Gracia Luigi-Sierra; Anna Castelló; Dailu Guan; Raquel Quintanilla; Raul Tonda; Marcel Amills
Journal:  Genet Sel Evol       Date:  2021-05-04       Impact factor: 4.297

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.